Study type: observational mechanistic. Interventions: in vitro IL-5 exposure and assessment of patients receiving anti-IL-5/anti-IL-5R biologics (monoclonal antibodies). Drug mechanisms: anti-IL-5 mAbs neutralize IL-5, anti-IL-5R mAbs block IL-5 receptor signaling—both reduce IL-5 activity beyond eosinophils, aiming to restore antiviral responses. Targets: bronchial epithelial cells and peripheral immune cells (PBMCs, especially dendritic cells). Pathways: IL-5/IL-5R signaling hypothesized to suppress rhinovirus-induced interferon (IFN) production, anti-IL-5 therapies expected to increase IFN-mediated antiviral immunity and reduce asthma exacerbation risk.